Skip to main content
BNGO
NASDAQ Industrial Applications And Services

Bionano Q3 Revenue Up 12% to $8.3M; FY26 Guidance Reiterated at $31-33M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.21
Mkt Cap
$17.195M
52W Low
$1
52W High
$2.23
52W Position info
21% above low
Off High info
46% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

BNGO sits 21% above its 52-week low of $1.

Summary

Bionano reported Q3 2026 revenue of $8.3M (up 12%), a 48% gross margin and 12% lower operating expenses, and reiterated FY26 revenue guidance of $31-33M. With cash of $4.355M against a $6.45M quarterly net loss, financing needs stay front and center.


Key Events · Earnings and Guidance · BNGO

  • Q3 Revenue Grows 12% to $8.3M

    Total revenue rose to $8.3M from $7.4M a year earlier, with consumables up 24% to $4.7M and 9,870 flowcells sold versus 8,390.

  • Margins Improve, Expenses Cut 12%

    Gross margin was 48% versus 46%, and operating expenses fell 12% to $10.5M ($8.8M adjusted), narrowing the quarterly net loss to $6.45M from $8.50M.

  • Cash Thin Against Quarterly Burn

    Cash and equivalents were $4.355M at September 30, 2026, versus a $6.45M net loss for the quarter; the going concern warning previously disclosed in the Q2 10-Q remains the key risk.

  • FY26 Guidance Reiterated at $31-33M

    Nine-month revenue of $23.1M leaves roughly $8-10M needed in Q4 to land inside the reiterated $31-33M range.


Analysis · BNGO · Industrial Applications And Services

The top line is moving in the right direction: revenue grew 12%, consumables rose 24%, and flowcell placements climbed 18%, all signs that the OGM installed base is being used more intensively. Gross margin also improved to 48% while operating expenses fell 12%. The balance sheet, however, is the real story. Cash and equivalents stood at $4.355M at September 30 against a $6.45M quarterly net loss, so the company still needs to raise money to keep operating, and the going concern warning previously disclosed in the Q2 10-Q remains the central risk. Reiterating $31-33M FY26 guidance against $23.1M booked in the first nine months implies roughly $8-10M in Q4, meaning even the low end requires a modest sequential step-up.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BNGO was trading at $1.21 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $17.2M. The 52-week trading range was $1.00 to $2.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BNGO - Latest Insights

BNGO
Nov 10, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.23
Real-time Price: $1.13 info
Change: -$0.0993 (-8%) info
Market Cap: $15.378M info
BNGO
Oct 30, 2026, 6:22 PM EDT
Filing Type: S-3/A
Importance Score:
7
Price at Filing: $1.19
Real-time Price: $1.13 info
Change: -$0.060 (-5%) info
Market Cap: $15.378M info
BNGO
Sep 14, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.24
Real-time Price: $1.13 info
Change: -$0.1093 (-9%) info
Market Cap: $15.378M info
BNGO
Aug 10, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.17
Real-time Price: $1.13 info
Change: -$0.0396 (-3%) info
Market Cap: $15.378M info
BNGO
Aug 10, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.17
Real-time Price: $1.13 info
Change: -$0.0395 (-3%) info
Market Cap: $15.378M info